Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Tizona Therapeutics, Inc
Pfizer
Turning Point Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
University of Pennsylvania
Novartis
Imugene Limited
Surrey Thoracic Surgery Group
Ikena Oncology
Multitude Therapeutics Inc.
Roswell Park Cancer Institute
Cantargia AB
Memorial Sloan Kettering Cancer Center
Innovent Biologics (Suzhou) Co. Ltd.
National Cancer Institute (NCI)
Novartis
MacroGenics
Bayer
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
University of Washington
Bayer
Medical University of South Carolina
University of Washington
Wake Forest University Health Sciences
Esanex Inc.
Alliance for Clinical Trials in Oncology
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Virginia Commonwealth University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
SWOG Cancer Research Network
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Pharmacyclics LLC.
National Cancer Institute (NCI)
National Cancer Institute (NCI)